Share Price and Basic Stock Data
Last Updated: May 23, 2025, 1:53 am
| PEG Ratio | 4.42 |
|---|
Competitors of Ajanta Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 103 | 247/84.3 | 20.9 | 36.5 | 0.00 % | 18.0 % | 15.5 % | 10.0 |
| MPS Pharmaa Ltd | 5.27 Cr. | 2.76 | 4.33/2.50 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 43.0 Cr. | 57.9 | 94.9/44.5 | 14.6 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 35.2 Cr. | 24.0 | 29.0/13.1 | 34.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,127.83 Cr | 1,124.12 | 78.84 | 190.81 | 0.32% | 16.10% | 17.19% | 6.19 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 838 | 870 | 951 | 938 | 972 | 882 | 1,021 | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 |
| Expenses | 598 | 664 | 729 | 742 | 802 | 732 | 750 | 738 | 791 | 776 | 815 | 875 | 825 |
| Operating Profit | 240 | 207 | 222 | 196 | 170 | 149 | 271 | 291 | 314 | 278 | 330 | 311 | 321 |
| OPM % | 29% | 24% | 23% | 21% | 17% | 17% | 27% | 28% | 28% | 26% | 29% | 26% | 28% |
| Other Income | 24 | 29 | 33 | 40 | 35 | 37 | 32 | 21 | 14 | 36 | 26 | 19 | 30 |
| Interest | 1 | 7 | 1 | 1 | 3 | 1 | 1 | 2 | 2 | 2 | 1 | 6 | 8 |
| Depreciation | 32 | 31 | 32 | 33 | 33 | 33 | 33 | 34 | 34 | 34 | 34 | 34 | 36 |
| Profit before tax | 231 | 198 | 222 | 203 | 168 | 152 | 269 | 276 | 291 | 278 | 322 | 290 | 307 |
| Tax % | 17% | 24% | 21% | 23% | 20% | 20% | 23% | 29% | 28% | 27% | 24% | 25% | 24% |
| Net Profit | 192 | 151 | 175 | 157 | 135 | 122 | 208 | 195 | 210 | 203 | 246 | 216 | 233 |
| EPS in Rs | 14.78 | 11.80 | 13.63 | 12.22 | 10.50 | 9.54 | 16.24 | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 |
Last Updated: March 3, 2025, 5:47 pm
Below is a detailed analysis of the quarterly data for Ajanta Pharma Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is 1,146.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,187.00 Cr. (Sep 2024) to 1,146.00 Cr., marking a decrease of 41.00 Cr..
- For Expenses, as of Dec 2024, the value is 825.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 875.00 Cr. (Sep 2024) to 825.00 Cr., marking a decrease of 50.00 Cr..
- For Operating Profit, as of Dec 2024, the value is 321.00 Cr.. The value appears strong and on an upward trend. It has increased from 311.00 Cr. (Sep 2024) to 321.00 Cr., marking an increase of 10.00 Cr..
- For OPM %, as of Dec 2024, the value is 28.00%. The value appears strong and on an upward trend. It has increased from 26.00% (Sep 2024) to 28.00%, marking an increase of 2.00%.
- For Other Income, as of Dec 2024, the value is 30.00 Cr.. The value appears strong and on an upward trend. It has increased from 19.00 Cr. (Sep 2024) to 30.00 Cr., marking an increase of 11.00 Cr..
- For Interest, as of Dec 2024, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Sep 2024) to 8.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Dec 2024, the value is 36.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Sep 2024) to 36.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Dec 2024, the value is 307.00 Cr.. The value appears strong and on an upward trend. It has increased from 290.00 Cr. (Sep 2024) to 307.00 Cr., marking an increase of 17.00 Cr..
- For Tax %, as of Dec 2024, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 25.00% (Sep 2024) to 24.00%, marking a decrease of 1.00%.
- For Net Profit, as of Dec 2024, the value is 233.00 Cr.. The value appears strong and on an upward trend. It has increased from 216.00 Cr. (Sep 2024) to 233.00 Cr., marking an increase of 17.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 18.64. The value appears strong and on an upward trend. It has increased from 17.33 (Sep 2024) to 18.64, marking an increase of 1.31.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: May 3, 2025, 3:18 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,208 | 1,474 | 1,749 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 |
| Expenses | 840 | 968 | 1,155 | 1,292 | 1,467 | 1,489 | 1,904 | 1,889 | 2,408 | 2,934 | 3,037 | 3,389 |
| Operating Profit | 369 | 505 | 594 | 691 | 658 | 567 | 683 | 1,001 | 933 | 808 | 1,172 | 1,260 |
| OPM % | 31% | 34% | 34% | 35% | 31% | 28% | 26% | 35% | 28% | 22% | 28% | 27% |
| Other Income | 14 | 8 | 14 | 20 | 24 | 21 | 88 | 24 | 112 | 74 | 85 | 94 |
| Interest | 9 | 6 | 5 | 1 | 0 | 1 | 12 | 8 | 10 | 6 | 7 | 21 |
| Depreciation | 44 | 52 | 44 | 61 | 60 | 72 | 96 | 116 | 125 | 131 | 135 | 144 |
| Profit before tax | 330 | 456 | 559 | 648 | 623 | 514 | 664 | 900 | 909 | 745 | 1,114 | 1,189 |
| Tax % | 29% | 32% | 26% | 22% | 25% | 25% | 30% | 27% | 22% | 21% | 27% | 23% |
| Net Profit | 234 | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 |
| EPS in Rs | 17.75 | 23.47 | 31.49 | 38.40 | 35.50 | 29.56 | 35.73 | 50.38 | 55.63 | 45.89 | 63.70 | 73.68 |
| Dividend Payout % | 15% | 17% | 17% | 23% | 0% | 20% | 24% | 13% | 11% | 15% | 79% | 38% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 32.48% | 34.19% | 21.88% | -7.50% | -17.48% | 20.93% | 39.74% | 9.02% | -17.53% | 38.78% | 12.75% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1.71% | -12.32% | -29.37% | -9.99% | 38.41% | 18.81% | -30.72% | -26.55% | 56.31% | -26.03% |
Ajanta Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 12% |
| 3 Years: | 12% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 9% |
| TTM: | 14% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 21% |
| 3 Years: | 31% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 23% |
| 3 Years: | 22% |
| Last Year: | 26% |
Last Updated: Unknown
Balance Sheet
Last Updated: May 13, 2025, 3:56 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 | 25 |
| Reserves | 576 | 823 | 1,173 | 1,550 | 2,024 | 2,228 | 2,581 | 2,978 | 3,247 | 3,363 | 3,542 | 3,600 |
| Borrowings | 130 | 72 | 81 | 1 | 2 | 36 | 75 | 31 | 25 | 36 | 35 | 31 |
| Other Liabilities | 226 | 233 | 207 | 254 | 383 | 383 | 619 | 702 | 711 | 1,159 | 927 | 898 |
| Total Liabilities | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,554 |
| Fixed Assets | 279 | 288 | 451 | 589 | 1,053 | 1,178 | 1,472 | 1,541 | 1,512 | 1,496 | 1,479 | 1,742 |
| CWIP | 94 | 170 | 240 | 339 | 61 | 262 | 132 | 108 | 153 | 209 | 256 | 176 |
| Investments | 63 | 60 | 86 | 182 | 190 | 78 | 79 | 176 | 147 | 535 | 349 | 482 |
| Other Assets | 513 | 629 | 703 | 713 | 1,122 | 1,147 | 1,610 | 1,904 | 2,188 | 2,341 | 2,446 | 2,154 |
| Total Assets | 949 | 1,146 | 1,479 | 1,823 | 2,426 | 2,664 | 3,293 | 3,729 | 4,000 | 4,582 | 4,530 | 4,554 |
Below is a detailed analysis of the balance sheet data for Ajanta Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 25.00 Cr..
- For Reserves, as of Mar 2025, the value is 3,600.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,542.00 Cr. (Mar 2024) to 3,600.00 Cr., marking an increase of 58.00 Cr..
- For Borrowings, as of Mar 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 35.00 Cr. (Mar 2024) to 31.00 Cr., marking a decrease of 4.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 898.00 Cr.. The value appears to be improving (decreasing). It has decreased from 927.00 Cr. (Mar 2024) to 898.00 Cr., marking a decrease of 29.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 4,554.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,530.00 Cr. (Mar 2024) to 4,554.00 Cr., marking an increase of 24.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1,742.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,479.00 Cr. (Mar 2024) to 1,742.00 Cr., marking an increase of 263.00 Cr..
- For CWIP, as of Mar 2025, the value is 176.00 Cr.. The value appears to be declining and may need further review. It has decreased from 256.00 Cr. (Mar 2024) to 176.00 Cr., marking a decrease of 80.00 Cr..
- For Investments, as of Mar 2025, the value is 482.00 Cr.. The value appears strong and on an upward trend. It has increased from 349.00 Cr. (Mar 2024) to 482.00 Cr., marking an increase of 133.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,154.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,446.00 Cr. (Mar 2024) to 2,154.00 Cr., marking a decrease of 292.00 Cr..
- For Total Assets, as of Mar 2025, the value is 4,554.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,530.00 Cr. (Mar 2024) to 4,554.00 Cr., marking an increase of 24.00 Cr..
Notably, the Reserves (3,600.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 239.00 | 433.00 | 513.00 | 690.00 | 656.00 | 531.00 | 608.00 | -30.00 | 908.00 | 772.00 | -34.00 | -30.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 59 | 61 | 64 | 78 | 59 | 79 | 82 | 109 | 93 | 111 | 103 | 108 |
| Inventory Days | 178 | 164 | 159 | 180 | 186 | 315 | 415 | 276 | 434 | 347 | 283 | 283 |
| Days Payable | 159 | 132 | 109 | 128 | 157 | 224 | 214 | 202 | 212 | 143 | 147 | 159 |
| Cash Conversion Cycle | 78 | 94 | 114 | 130 | 88 | 170 | 282 | 184 | 315 | 315 | 240 | 233 |
| Working Capital Days | 59 | 57 | 61 | 90 | 65 | 103 | 119 | 116 | 127 | 141 | 84 | 120 |
| ROCE % | 39% | 55% | 57% | 52% | 46% | 34% | 24% | 27% | 32% | 29% | 23% | 32% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 1,977,744 | 0.94 | 430.01 | 1,977,744 | 2025-04-22 17:25:43 | 0% |
| UTI Flexi Cap Fund | 1,851,478 | 1.6 | 402.56 | 1,851,478 | 2025-04-22 17:25:43 | 0% |
| Kotak Small Cap Fund - Regular Plan | 992,271 | 1.5 | 215.74 | 992,271 | 2025-04-22 17:25:43 | 0% |
| Nippon India Pharma Fund | 968,214 | 3.05 | 210.51 | 968,214 | 2025-04-22 15:57:00 | 0% |
| Invesco India Contra Fund | 775,259 | 1.26 | 168.56 | 775,259 | 2025-04-22 17:25:43 | 0% |
| HDFC Large and Mid Cap Fund - Regular Plan | 674,373 | 0.91 | 146.63 | 674,373 | 2025-04-22 15:57:00 | 0% |
| Nippon India Multi Cap Fund | 628,966 | 0.53 | 136.75 | 628,966 | 2025-04-22 15:57:00 | 0% |
| Canara Robeco Small Cap Fund | 546,991 | 1.24 | 118.93 | 546,991 | 2025-04-22 15:57:00 | 0% |
| Franklin India Prima Fund | 527,173 | 1.14 | 114.62 | 527,173 | 2025-04-22 15:57:00 | 0% |
| Mirae Asset Midcap Fund | 510,521 | 0.77 | 111 | 510,521 | 2025-04-22 17:25:43 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 64.82 | 45.89 | 82.45 | 75.09 | 53.60 |
| Diluted EPS (Rs.) | 64.77 | 45.89 | 82.45 | 75.09 | 53.60 |
| Cash EPS (Rs.) | 75.31 | 56.89 | 97.61 | 88.55 | 64.24 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 282.34 | 268.14 | 380.24 | 344.52 | 296.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 282.34 | 268.14 | 380.24 | 344.52 | 296.34 |
| Revenue From Operations / Share (Rs.) | 333.10 | 296.21 | 389.17 | 332.34 | 295.08 |
| PBDIT / Share (Rs.) | 99.45 | 69.80 | 121.72 | 117.83 | 88.43 |
| PBIT / Share (Rs.) | 88.73 | 59.45 | 107.13 | 104.48 | 77.51 |
| PBT / Share (Rs.) | 88.16 | 58.98 | 105.94 | 103.53 | 75.71 |
| Net Profit / Share (Rs.) | 64.60 | 46.54 | 83.01 | 75.20 | 53.33 |
| NP After MI And SOA / Share (Rs.) | 64.60 | 46.54 | 83.01 | 75.20 | 53.33 |
| PBDIT Margin (%) | 29.85 | 23.56 | 31.27 | 35.45 | 29.96 |
| PBIT Margin (%) | 26.63 | 20.06 | 27.52 | 31.43 | 26.26 |
| PBT Margin (%) | 26.46 | 19.91 | 27.22 | 31.15 | 25.65 |
| Net Profit Margin (%) | 19.39 | 15.71 | 21.33 | 22.62 | 18.07 |
| NP After MI And SOA Margin (%) | 19.39 | 15.71 | 21.33 | 22.62 | 18.07 |
| Return on Networth / Equity (%) | 22.87 | 17.35 | 21.83 | 21.82 | 17.99 |
| Return on Capital Employeed (%) | 29.95 | 21.21 | 26.98 | 29.02 | 25.06 |
| Return On Assets (%) | 17.59 | 12.56 | 17.57 | 17.30 | 14.09 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 0.90 | 0.81 | 0.83 | 0.79 | 0.76 |
| Current Ratio (X) | 3.05 | 2.49 | 3.50 | 3.13 | 2.71 |
| Quick Ratio (X) | 2.12 | 1.77 | 2.28 | 1.94 | 1.89 |
| Inventory Turnover Ratio (X) | 1.14 | 1.19 | 1.10 | 1.25 | 1.28 |
| Dividend Payout Ratio (NP) (%) | 78.68 | 15.25 | 11.53 | 12.67 | 24.25 |
| Dividend Payout Ratio (CP) (%) | 67.48 | 12.47 | 9.81 | 10.76 | 20.13 |
| Earning Retention Ratio (%) | 21.32 | 84.75 | 88.47 | 87.33 | 75.75 |
| Cash Earning Retention Ratio (%) | 32.52 | 87.53 | 90.19 | 89.24 | 79.87 |
| Interest Coverage Ratio (X) | 174.28 | 151.01 | 102.45 | 123.89 | 65.11 |
| Interest Coverage Ratio (Post Tax) (X) | 114.20 | 101.68 | 70.87 | 80.07 | 40.60 |
| Enterprise Value (Cr.) | 28149.11 | 14945.61 | 15321.67 | 15384.30 | 11819.91 |
| EV / Net Operating Revenue (X) | 6.69 | 3.99 | 4.59 | 5.32 | 4.57 |
| EV / EBITDA (X) | 22.40 | 16.95 | 14.66 | 15.02 | 15.24 |
| MarketCap / Net Operating Revenue (X) | 6.72 | 4.08 | 4.65 | 5.40 | 4.63 |
| Retention Ratios (%) | 21.31 | 84.74 | 88.46 | 87.32 | 75.74 |
| Price / BV (X) | 7.93 | 4.51 | 4.76 | 5.21 | 4.61 |
| Price / Net Operating Revenue (X) | 6.72 | 4.08 | 4.65 | 5.40 | 4.63 |
| EarningsYield | 0.02 | 0.03 | 0.04 | 0.04 | 0.03 |
After reviewing the key financial ratios for Ajanta Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 64.82. This value is within the healthy range. It has increased from 45.89 (Mar 23) to 64.82, marking an increase of 18.93.
- For Diluted EPS (Rs.), as of Mar 24, the value is 64.77. This value is within the healthy range. It has increased from 45.89 (Mar 23) to 64.77, marking an increase of 18.88.
- For Cash EPS (Rs.), as of Mar 24, the value is 75.31. This value is within the healthy range. It has increased from 56.89 (Mar 23) to 75.31, marking an increase of 18.42.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 282.34. It has increased from 268.14 (Mar 23) to 282.34, marking an increase of 14.20.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 282.34. It has increased from 268.14 (Mar 23) to 282.34, marking an increase of 14.20.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 333.10. It has increased from 296.21 (Mar 23) to 333.10, marking an increase of 36.89.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 99.45. This value is within the healthy range. It has increased from 69.80 (Mar 23) to 99.45, marking an increase of 29.65.
- For PBIT / Share (Rs.), as of Mar 24, the value is 88.73. This value is within the healthy range. It has increased from 59.45 (Mar 23) to 88.73, marking an increase of 29.28.
- For PBT / Share (Rs.), as of Mar 24, the value is 88.16. This value is within the healthy range. It has increased from 58.98 (Mar 23) to 88.16, marking an increase of 29.18.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 46.54 (Mar 23) to 64.60, marking an increase of 18.06.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 64.60. This value is within the healthy range. It has increased from 46.54 (Mar 23) to 64.60, marking an increase of 18.06.
- For PBDIT Margin (%), as of Mar 24, the value is 29.85. This value is within the healthy range. It has increased from 23.56 (Mar 23) to 29.85, marking an increase of 6.29.
- For PBIT Margin (%), as of Mar 24, the value is 26.63. This value exceeds the healthy maximum of 20. It has increased from 20.06 (Mar 23) to 26.63, marking an increase of 6.57.
- For PBT Margin (%), as of Mar 24, the value is 26.46. This value is within the healthy range. It has increased from 19.91 (Mar 23) to 26.46, marking an increase of 6.55.
- For Net Profit Margin (%), as of Mar 24, the value is 19.39. This value exceeds the healthy maximum of 10. It has increased from 15.71 (Mar 23) to 19.39, marking an increase of 3.68.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.39. This value is within the healthy range. It has increased from 15.71 (Mar 23) to 19.39, marking an increase of 3.68.
- For Return on Networth / Equity (%), as of Mar 24, the value is 22.87. This value is within the healthy range. It has increased from 17.35 (Mar 23) to 22.87, marking an increase of 5.52.
- For Return on Capital Employeed (%), as of Mar 24, the value is 29.95. This value is within the healthy range. It has increased from 21.21 (Mar 23) to 29.95, marking an increase of 8.74.
- For Return On Assets (%), as of Mar 24, the value is 17.59. This value is within the healthy range. It has increased from 12.56 (Mar 23) to 17.59, marking an increase of 5.03.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.90. It has increased from 0.81 (Mar 23) to 0.90, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 24, the value is 3.05. This value exceeds the healthy maximum of 3. It has increased from 2.49 (Mar 23) to 3.05, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 24, the value is 2.12. This value exceeds the healthy maximum of 2. It has increased from 1.77 (Mar 23) to 2.12, marking an increase of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.14. This value is below the healthy minimum of 4. It has decreased from 1.19 (Mar 23) to 1.14, marking a decrease of 0.05.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 78.68. This value exceeds the healthy maximum of 50. It has increased from 15.25 (Mar 23) to 78.68, marking an increase of 63.43.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 67.48. This value exceeds the healthy maximum of 50. It has increased from 12.47 (Mar 23) to 67.48, marking an increase of 55.01.
- For Earning Retention Ratio (%), as of Mar 24, the value is 21.32. This value is below the healthy minimum of 40. It has decreased from 84.75 (Mar 23) to 21.32, marking a decrease of 63.43.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 32.52. This value is below the healthy minimum of 40. It has decreased from 87.53 (Mar 23) to 32.52, marking a decrease of 55.01.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 174.28. This value is within the healthy range. It has increased from 151.01 (Mar 23) to 174.28, marking an increase of 23.27.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 114.20. This value is within the healthy range. It has increased from 101.68 (Mar 23) to 114.20, marking an increase of 12.52.
- For Enterprise Value (Cr.), as of Mar 24, the value is 28,149.11. It has increased from 14,945.61 (Mar 23) to 28,149.11, marking an increase of 13,203.50.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 6.69. This value exceeds the healthy maximum of 3. It has increased from 3.99 (Mar 23) to 6.69, marking an increase of 2.70.
- For EV / EBITDA (X), as of Mar 24, the value is 22.40. This value exceeds the healthy maximum of 15. It has increased from 16.95 (Mar 23) to 22.40, marking an increase of 5.45.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 6.72. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 23) to 6.72, marking an increase of 2.64.
- For Retention Ratios (%), as of Mar 24, the value is 21.31. This value is below the healthy minimum of 30. It has decreased from 84.74 (Mar 23) to 21.31, marking a decrease of 63.43.
- For Price / BV (X), as of Mar 24, the value is 7.93. This value exceeds the healthy maximum of 3. It has increased from 4.51 (Mar 23) to 7.93, marking an increase of 3.42.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 6.72. This value exceeds the healthy maximum of 3. It has increased from 4.08 (Mar 23) to 6.72, marking an increase of 2.64.
- For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ajanta Pharma Ltd:
- Net Profit Margin: 19.39%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 29.95% (Industry Average ROCE: 16.1%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 22.87% (Industry Average ROE: 17.19%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 114.2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 34.9 (Industry average Stock P/E: 78.84)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.39%
About the Company - Qualitative Analysis
Ajanta Pharma Ltd. is a Public Limited Listed company incorporated on 31/12/1979 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1979PLC022059 and registration number is 022059. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 4322.04 Cr. and Equity Capital is Rs. 25.07 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Ajanta House, Charkop, Mumbai Maharashtra 400067 | info@ajantapharma.com http://www.ajantapharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mannalal B Agrawal | Chairman |
| Mr. Madhusudan B Agrawal | Vice Chairman |
| Mr. Yogesh M Agrawal | Managing Director |
| Mr. Rajesh M Agrawal | Joint Managing Director |
| Mr. K H Viswanathan | Independent Director |
| Mr. Prabhakar R Dalal | Independent Director |
| Dr. Anjana Grewal | Independent Director |
| Mr. Chandrakant M Khetan | Independent Director |
FAQ
What is the intrinsic value of Ajanta Pharma Ltd?
Ajanta Pharma Ltd's intrinsic value (as of 22 May 2025) is ₹2101.80 — 18.34% lower the current market price of 2,574.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 32,135 Cr. market cap, FY2025-2026 high/low of ₹3,486/2,022, reserves of 3,600 Cr, and liabilities of 4,554 Cr.
What is the Market Cap of Ajanta Pharma Ltd?
The Market Cap of Ajanta Pharma Ltd is 32,135 Cr..
What is the current Stock Price of Ajanta Pharma Ltd as on 22 May 2025?
The current stock price of Ajanta Pharma Ltd as on 22 May 2025 is 2,574.
What is the High / Low of Ajanta Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Ajanta Pharma Ltd stocks is ₹3,486/2,022.
What is the Stock P/E of Ajanta Pharma Ltd?
The Stock P/E of Ajanta Pharma Ltd is 34.9.
What is the Book Value of Ajanta Pharma Ltd?
The Book Value of Ajanta Pharma Ltd is 290.
What is the Dividend Yield of Ajanta Pharma Ltd?
The Dividend Yield of Ajanta Pharma Ltd is 1.40 %.
What is the ROCE of Ajanta Pharma Ltd?
The ROCE of Ajanta Pharma Ltd is 33.3 %.
What is the ROE of Ajanta Pharma Ltd?
The ROE of Ajanta Pharma Ltd is 25.6 %.
What is the Face Value of Ajanta Pharma Ltd?
The Face Value of Ajanta Pharma Ltd is 2.00.